[HTML][HTML] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3 …
…, S Prasad, D Das, D Raju, U Praturi… - The Lancet Infectious …, 2021 - thelancet.com
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg)
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …
[HTML][HTML] Protective efficacy of Zika vaccine in AG129 mouse model
…, N Bonguram, R Eligeti, S Gadiyaram, U Praturi… - Scientific reports, 2017 - nature.com
Zika virus (ZIKV) is a mosquito-borne flavivirus that causes asymptomatic infection or presents
only mild symptoms in majority of those infected. However, vaccination for ZIKV is a public …
only mild symptoms in majority of those infected. However, vaccination for ZIKV is a public …
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of …
…, B Ganneru, S Prasad, D Das, D Raju, U Praturi… - medRxiv, 2020 - medrxiv.org
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 µg or 6 µg)
formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Earlier, …
formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Earlier, …
Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial
…, B Ganneru, S Reddy, H Jogdand, D Raju, U Praturi… - MedRxiv, 2022 - medrxiv.org
Background Neutralising antibody responses to SARS-CoV-2 vaccines have been reported
to decline within 6 months of vaccination, particularly against Variants of Concern (VOC). We …
to decline within 6 months of vaccination, particularly against Variants of Concern (VOC). We …
[HTML][HTML] Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®)
One of the most preferable characteristics for a COVID-19 vaccine candidate is the ability to
reduce transmission and infection of SARS-CoV-2, in addition to disease prevention. Unlike …
reduce transmission and infection of SARS-CoV-2, in addition to disease prevention. Unlike …
[PDF][PDF] COVID19 vaccine: COVAXIN®-India's first indigenous effective weapon to fight against coronavirus (A Review)
Since the pandemic began (COVID19), India has confirmed more than 11 million cases and
over 157,000 deaths. The country has recorded the second-highest number of Covid-19 …
over 157,000 deaths. The country has recorded the second-highest number of Covid-19 …
Vaccination Worldwide: Strategies, Distribution and Challenges
C Samal, K Jakimowicz, K Dasgupta… - arXiv preprint arXiv …, 2021 - arxiv.org
The Coronavirus 2019 (Covid-19) pandemic caused by the SARS-CoV-2 virus represents an
unprecedented crisis for our planet. It is a bane of the \"uber connected world that we live in …
unprecedented crisis for our planet. It is a bane of the \"uber connected world that we live in …
Study of Awareness Regarding Covid-19 Vaccines Among General Population
V Patel, K Patel - 2021 - researchsquare.com
BACKGROUND: The COVID-19 pandemic is an ongoing global pandemic of coronavirus
disease 2019 caused by SARS-Cov-2. COVID-19 Vaccines are developed to provide immunity …
disease 2019 caused by SARS-Cov-2. COVID-19 Vaccines are developed to provide immunity …
Desenvolvimento de estratégia vacinal contra o Zika Vírus utilizando a levedura Pichia Pastoris como carreadora de antígenos
AJD SILVA - 2020 - repositorio.ufpe.br
Leveduras, como Pichia pastoris, vêm sendo exploradas não apenas para produção de
proteínas recombinantes, mas também como carreadoras de antígenos em estratégias vacinais…
proteínas recombinantes, mas também como carreadoras de antígenos em estratégias vacinais…